Peptides · Peptide comparison
Cartalax vs Livagen
Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression
Tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that directly penetrates cell nuclei and binds double-stranded DNA to induce chromatin decondensation in senescent lymphocytes, activate ribosomal genes, inhibit enkephalin-degrading enzymes with an IC50 of 20 μM, and restore protein synthesis capacity in aging cells through selective epigenetic remodeling
- Anti-Aging
- Anti-Aging
At a glance
Quick comparison
Efficacy
Benefit ratings
Anti-Aging
Healing & Recovery
Hormone Support
Cell Renewal
Liver Support
DNA Protection
Technical data
Compound specifications
Cartalax
- Molecular formula
- C12H19N3O8
- Molecular weight
- 333.3 g/mol
- Half-life
- Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
- Bioavailability
- Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
- CAS number
- Not yet registered (research compound)
Livagen
- Molecular formula
- C18H31N5O9
- Molecular weight
- 461.5 g/mol
- Half-life
- Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
- Bioavailability
- Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli
- CAS number
- Not assigned (research compound)
Protocols
Dosing compared
Cartalax
Subcutaneous
- 200 mcgOnce daily · 10-day cycles, repeated periodicallyCartalax has only lab and cell-culture research, so there is no trial-set human dose. In practice it is commonly given as 200 mcg daily in short 10-day cycles, matching how other Khavinson short peptides are used [3][4].
Livagen
Intramuscular
- 5-10 mgOnce daily · 10-day course (50-100 mg total)Reflects the Khavinson-laboratory bioregulator course used in practice: a total of 50-100 mg of the KEDA tetrapeptide delivered over 10 days. Livagen has no standardized human clinical dosing; evidence is largely preclinical [6].
Applications
Best suited for
Cartalax
- Cartilage regeneration and protection in age-related osteoarthritis
- Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Connective tissue repair and maintenance in aging individuals
- Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
- Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Livagen
- Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
- Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Supporting liver function and hepatoprotection in the context of aging
- Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Restoring protein synthesis and ribosomal function in elderly individuals
- Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Khavinson bioregulator protocols for anti-aging and longevity
- Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Cartalax
Common
- Mild injection site reaction
- Mild GI discomfort
- Mild fatigue
- Transient joint stiffness
Uncommon
- Temporary increase in joint discomfort
Serious
- No documented serious adverse effects
Livagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Digestive enzyme changes
Uncommon
- Transient flu-like symptoms
Serious
- No documented serious adverse effects
Research status
Safety & evidence
Cartalax
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active joint infection — treat infection before initiating peptide bioregulator therapy
- Malignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated
Livagen
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active autoimmune conditions in flare without physician supervision
- Concurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism
Decision guide
Which is right for you?
Cartalax
Choose Cartalax if…
- Cartilage regeneration and protection in age-related osteoarthritis
- Connective tissue repair and maintenance in aging individuals
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Livagen
Choose Livagen if…
- Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
- Supporting liver function and hepatoprotection in the context of aging
- Restoring protein synthesis and ribosomal function in elderly individuals
- Khavinson bioregulator protocols for anti-aging and longevity